Medical Care

Skip Navigation LinksHome > August 2014 - Volume 52 - Issue 8 > Changes in Use of Lipid-lowering Medications Among Black and...
Medical Care:
doi: 10.1097/MLR.0000000000000159
Original Articles

Changes in Use of Lipid-lowering Medications Among Black and White Dual Enrollees With Diabetes Transitioning From Medicaid to Medicare Part D Drug Coverage

Adams, Alyce S. PhD*; Madden, Jeanne M. PhD; Zhang, Fang PhD; Soumerai, Stephen B. ScD; Gilden, Dan MS; Griggs, Jennifer MD§; Trinacty, Connie M. PhD; Bishop, Christine PhD; Ross-Degnan, Dennis ScD

Supplemental Author Material
Collapse Box


Background: The use of lipid-lowering agents is suboptimal among dual enrollees, particularly blacks.

Objectives: To determine whether the removal of restrictive drug caps under Medicare Part D reduced racial differences among dual enrollees with diabetes.

Research Design: An interrupted time series with comparison series design (ITS) cohort study.

Subjects: A total of 8895 black and white diabetes patients aged 18 years and older drawn from a nationally representative sample of fee-for-service dual enrollees (January 2004–December 2007) in states with and without drug caps before Part D.

Measures: We examined the monthly (1) proportion of patients with any use of lipid-lowering therapies; and (2) intensity of use. Stratification measures included age (less than 65, 65 y and older), race (white vs. black), and sex.

Results: At baseline, lipid-lowering drug use was higher in no drug cap states (drug cap: 54.0% vs. nondrug cap: 66.8%) and among whites versus blacks (drug cap: 58.5% vs. 44.9%, no drug cap: 68.4% vs. 61.9%). In strict drug cap states only, Part D was associated with an increase in the proportion with any use [nonelderly: +0.07 absolute percentage points (95% confidence interval, 0.06–0.09), P<0.001; elderly: +0.08 (0.06–0.10), P<0.001] regardless of race. However, we found no evidence of a change in the white-black gap in the proportion of users despite the removal of a significant financial barrier.

Conclusions: Medicare Part D was associated with increased use of lipid-lowering drugs, but racial gaps persisted. Understanding non–coverage-related barriers is critical in maximizing the potential benefits of coverage expansions for disparities reduction.

© 2014 by Lippincott Williams & Wilkins.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.